Published in:
Volume 1 / Year 2012 / Issue 3-4

Health professionals in the risk communication process on counterfeit medicines

Page: 135-7

Abstract:  Communication is a key component in the fight against counterfeit medicines affecting the lives of patients. Two types of risk communication should be distinguished: pro-active and reactive. Reactive communication… Read More »

Terminology for biosimilars–a confusing minefield

Author(s): ,
Page: 132-4

Author byline as per print journal: Robin Thorpe, PhD, FRCPath; Meenu Wadhwa, PhD Abstract:  Biosimilars are firmly established in the EU as copy biologicals with a clear and effective regulatory route for… Read More »

Go Back Print